All,
This of course has a massive gap. However, it has had a rough prior history however day traders won't see it that way. Once it gains traction upwards this could move fast and not only to $6-$7 but fill that massive gap. I am not suggestions a long hold necessarily, but a hold at this level would not be horrible. Either way based on recent positibve news and TA should be a winner sooner rather than later.
"Aprea Therapeutics: Believes Its Cash and Cash Equivalents as of Dec 31, 2020 Will Be Sufficient to Meet Its Current Projected Operating Requirements Into 2023 "
"Aprea Therapeutics Granted FDA Orphan Drug Designation for Eprenetapopt to Treat Leukemia"
This of course has a massive gap. However, it has had a rough prior history however day traders won't see it that way. Once it gains traction upwards this could move fast and not only to $6-$7 but fill that massive gap. I am not suggestions a long hold necessarily, but a hold at this level would not be horrible. Either way based on recent positibve news and TA should be a winner sooner rather than later.
"Aprea Therapeutics: Believes Its Cash and Cash Equivalents as of Dec 31, 2020 Will Be Sufficient to Meet Its Current Projected Operating Requirements Into 2023 "
"Aprea Therapeutics Granted FDA Orphan Drug Designation for Eprenetapopt to Treat Leukemia"
コメント:
garbo volume but still active on calls
コメント:
well had the bottom right got rejected one more time but overall... like I said patience on this one all that really mattered